×
Telesis Bio EBITDA 2021-2024 | TBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Telesis Bio ebitda from 2021 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Telesis Bio EBITDA 2021-2024 | TBIO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Telesis Bio ebitda from 2021 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$141.6B
Bristol Myers Squibb (BMY)
$116.3B
Gilead Sciences (GILD)
$115.4B
Vertex Pharmaceuticals (VRTX)
$102.3B
CSL (CSLLY)
$83.8B
Regeneron Pharmaceuticals (REGN)
$77.1B
GSK (GSK)
$69.6B
Argenex SE (ARGX)
$37.7B
Alnylam Pharmaceuticals (ALNY)
$31.7B
BioNTech SE (BNTX)
$27.1B
Illumina (ILMN)
$21.6B
Biogen (BIIB)
$21.3B
BeiGene (BGNE)
$17.2B
Moderna (MRNA)
$15.2B
Genmab (GMAB)
$13.4B
Incyte (INCY)
$13.3B
Insmed (INSM)
$12.6B
BioMarin Pharmaceutical (BMRN)
$12.5B
Bio-Techne Corp (TECH)
$11.6B
Sarepta Therapeutics (SRPT)
$11.4B
Exact Sciences (EXAS)
$11B
Vaxcyte (PCVX)
$10.8B
QIAGEN (QGEN)
$10.2B
Swedish Orphan Biovitrum (BIOVF)
$10.2B
Exelixis (EXEL)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$8.8B
Roivant Sciences (ROIV)
$8.4B
Ascendis Pharma (ASND)
$8.3B
Repligen (RGEN)
$8.1B